A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Licogliflozin (Primary)
- Indications Polycystic ovary syndrome
- Focus Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Nov 2021 Primary endpoint (Change in average morning fasting free testosterone blood concentrations from baseline) has not been met, as per results published in the Diabetes, Obesity and Metabolism.
- 01 Nov 2021 Results assessing the effect of licogliflozin on androgens in women with polycystic ovary syndrome, published in the Diabetes, Obesity and Metabolism.
- 09 Jul 2018 Status changed from recruiting to completed.